Puygrenier Pierre, Deniziaut Gabrielle, Gaujoux Sebastien, Vinh Jeanne Yen Khe Duong, Buffet Camille, Menegaux Fabrice, Chereau Nathalie
Department of General, Visceral, and Endocrine Surgery, Pitié-Salpêtrière Hospital AP-HP, Paris, France.
Sorbonne University, Paris, France.
World J Surg. 2025 Jul 25. doi: 10.1002/wjs.70018.
Oncocytic thyroid carcinoma (OTC) is recognized as a distinct entity of follicular thyroid carcinoma (FTC), and its prognosis has traditionally been considered poor. However, the available data on this topic remain limited and highly heterogeneous. The objective of this study was to investigate the clinicopathological features and prognosis of patients with OTC and compare them with those of patients with FTC.
A retrospective comparative study of all patients who underwent total thyroidectomy for OTC or FTC in a high-volume endocrine surgery center between January 2005 and December 2021. Demographic and clinicopathological characteristics, complications, and recurrence rates were compared using univariate and multivariate regression analyses.
In total, 347 patients, 72% female, median age 48 years (35-61 years) were enrolled, including 123 with OTC and 224 with FTC. Patients were significantly older in the OTC group than in the FTC group (54.7 vs. 44.5 years, respectively, p = 0.001). With respect to other demographic, clinical, and pathological characteristics, no statistically significant differences were observed between the two groups. The median follow-up duration was 5.6 years (3.2-10.5 years). Eighteen patients (5.2%) experienced recurrence, including 7 (5.7%) in the OTC group and 11 (4.9%) in the FTC group. No difference in recurrence-free survival was observed between the OTC and FTC groups (p = 0.47). In multivariate analysis, histological type was not associated with the risk of recurrence.
Patients withOTC have the same recurrence rate as do patients with FTC . It does not appear justified to propose a different therapeutic management for this histological type, and a stepdown management could be proposed.
嗜酸细胞性甲状腺癌(OTC)被认为是滤泡状甲状腺癌(FTC)的一种独特类型,其预后传统上被认为较差。然而,关于这一主题的现有数据仍然有限且高度异质性。本研究的目的是调查OTC患者的临床病理特征和预后,并将其与FTC患者进行比较。
对2005年1月至2021年12月期间在一家大型内分泌外科中心因OTC或FTC接受全甲状腺切除术的所有患者进行回顾性比较研究。使用单因素和多因素回归分析比较人口统计学和临床病理特征、并发症及复发率。
共纳入347例患者,其中72%为女性,中位年龄48岁(35 - 61岁),包括123例OTC患者和224例FTC患者。OTC组患者的年龄显著大于FTC组(分别为54.7岁和44.5岁,p = 0.001)。在其他人口统计学、临床和病理特征方面,两组之间未观察到统计学显著差异。中位随访时间为5.6年(3.2 - 10.5年)。18例患者(5.2%)出现复发,其中OTC组7例(5.7%),FTC组11例(4.9%)。OTC组和FTC组之间在无复发生存率方面未观察到差异(p = 0.47)。在多因素分析中,组织学类型与复发风险无关。
OTC患者的复发率与FTC患者相同。对于这种组织学类型提出不同的治疗管理方案似乎不合理,可以提出降级管理方案。